Bay­er’s block­buster pipeline promis­es bro­ken by a PhII set­back for top can­cer drug

Bay­er tout­ed its ex­per­i­men­tal can­cer drug ane­tum­ab rav­tan­sine as a $2 bil­lion-plus peak earn­er in the mak­ing for the phar­ma com­pa­ny. And it just flopped in its first mid-stage study — this one fo­cused on rare cas­es of mesothe­lioma.

Bay­er will de­tail the da­ta lat­er, but in­ves­ti­ga­tors say the drug flunked a Phase II study with a pri­ma­ry end­point of pro­gres­sion free sur­vival. The drug is al­so cur­rent­ly in 6 oth­er ear­ly stage stud­ies for a va­ri­ety of tu­mor types.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters